Ok, it was just 16 people but....
They have announced positive interim data from Phase 1a trial of a PSMA-TRACTr therapy, JANX007, for metastatic castration-resistant prostate cancer (mCRPC).
In the trial, JANX007 showed a high PSA response rate with all 16 patients experiencing at least a 50% decline in their PSA levels. Additionally, 63% of patients achieved at least a 90% PSA decline and 31% reached a 99% decline. The therapy also demonstrated durable PSA responses, with 75% of patients maintaining PSA50 declines and 50% maintaining PSA90 declines for a minimum of 12 weeks. These results, are coupled with an encouraging anti-tumor activity and a well-tolerated safety profile.
And maximum dosage has not been reached yet...
Oh, they are recruiting to expand the trial!
Advaxis--a Company with 2 Prostate Cancer Vaccine Candidates
Modified Citrus Pectin